Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEX-AZA: azacitidine for VEXAS syndrome
2024-510715-30-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in VEXAS syndrome (VEXAS), sponsored by Rigshospitalet. Primary endpoint: UBA1 variant allele frequency response after six cycles. Planned start Sep 2024; status: authorised.
02
Drugs
azacitidine
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on 2024-510715-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510715-30-00.